Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 201,1 and Aug. 21, 2023, in certain U.S. states.

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

Status: In progress

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation

The deadline to submit a claim has passed.

  • Deadline to file a claim: 02/17/2024
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: Varies
  • Total Settlement Amount: $30 million
  • Locations
    • Alabama
    • Alaska
    • Arizona
    • Arkansas
    • Colorado
    • Delaware
    • District of Columbia
    • California
    • Florida
    • Georgia
    • Hawaii
    • Idaho
    • Illinois
    • Kansas
    • Nebraska
    • Kentucky
    • Louisiana
    • Maine
    • Maryland
    • Massachusetts
    • Michigan
    • Minnesota
    • Mississippi
    • Missouri
    • Montana
    • Nevada
    • New Hampshire
    • New Jersey
    • Connecticut
    • New Mexico
    • New York
    • North Carolina
    • North Dakota
    • Oklahoma
    • Oregon
    • Pennsylvania
    • Rhode Island
    • South Carolina
    • South Dakota
    • Tennessee
    • Texas
    • Utah
    • Vermont
    • Virginia
    • Washington
    • West Virginia
    • Wisconsin
    • Wyoming

By Top Class Actions  |  September 1, 2023

Category: Closed Class Actions

This settlement is closed!

Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!

A Suboxone box, representing the Suboxone class action lawsuit settlement.
(Photo Credit: PureRadiancePhoto/Shutterstock)

Update:

  • Final approval for this class action settlement was granted Dec. 4, 2023.
  • Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

Indivior agreed to a $30 million antitrust class action lawsuit settlement to resolve claims that it worked with other companies to raise the cost of Suboxone, a treatment for opioid addiction.

The settlement benefits individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011 and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia.

The antitrust class action lawsuit accused Indivior of conspiring with other companies to raise the price of Suboxone and its generic alternatives. According to the plaintiffs in the case, they were forced to overpay for Suboxone as a result of the antitrust scheme. 

Individor is a pharmaceutical company that specializes in addiction and mental health treatment. 

Indivior hasn’t admitted any wrongdoing but agreed to a $30 million settlement to resolve the antitrust class action lawsuit.

Under the terms of the Suboxone class action settlement, class members can receive a proportional share of the net settlement fund based on the amount they spent in qualifying purchases. Exact payments will vary depending on the number of claims filed and other factors. 

The deadline for exclusion is Oct. 12, 2023. The objection deadline is Oct. 5, 2023.

The final approval hearing for the Suboxone antitrust class action lawsuit settlement is scheduled for Oct. 19, 2023.

In order to receive a settlement payment, class members must submit a valid claim form by Feb. 17, 2024.

Who’s Eligible

Individuals and entities who indirectly purchased or paid for Suboxone and its AB-rated generic equivalents for themselves, their families, employees, plan participants, beneficiaries or insureds between Dec. 22, 2011, and Aug. 21, 2023, in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia

Potential Award

Varies

Proof of Purchase

Records from the class member’s pharmacy showing they purchased Suboxone and its AB‐rated generic equivalents at least once or a note or records from their doctor describing the amount of Suboxone and its AB‐rated generic equivalents prescribed.

Class members may have a claim even if they are not able to provide any of the above claim documentation as long as they provide the certification on the claim form. However, the settlement administrator may ask those who do not provide the above documentation for additional claim documentation after the class member submits their claim form. 

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

02/17/2024

Case Name

In re: Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation, Case No. 2:13-md-02445-MSG, in the U.S. District Court for the Eastern District of Pennsylvania

Final Hearing

10/19/2023

Settlement Website
Claims Administrator

Suboxone End-Payor Antitrust Litigation
c/o A.B. Data, Ltd.
P.O. Box 173080
Milwaukee, WI 53217
[email protected]
877-311-3735

Class Counsel

Kenneth A Wexler
WEXLER BOLEY & ELGERSMA LLP

Steve Shadowen
HILLIARD SHADOWEN LLP

Michael M. Buchman
MOTLEY RICE LLC

Marvin A Miller
MILLER LAW LLC

Jeffrey L Kodroff
SPECTOR ROSEMAN & KODROFF PC

Defense Counsel

Justin Bernick
HOGAN LOVELLS US LLP

Read About More Class Action Lawsuits & Class Action Settlements:

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

383 thoughts onSuboxone indirect purchasers antitrust $30M class action settlement

  1. Belew says:

    Based on a very limited data set, we have seen claim amounts pleasantly more than expected and in the vicinity of 25% of overall claim amounts for total submitted claim values that were less than $15K.

  2. RandyAndy says:

    where the the check being posted from? I am looking to see when it may arrive in my informed delivery, I am in Boston MA.

  3. Kuy says:

    My claim was 85k I got back $13,070 NY

    1. Bobby says:

      $85,000? Really come on now. How many subs were you getting a month 1,000? A monthly script cost no more than $300 or less. Unless you were taking 5 subs a day or more. Let’s say $300 a month times 12 months would take you 23 years to spend $85,000 on sub scripts. It’s very hard to believe you spent $85:000 on subs scripts in 10 years. My brother paid for 5 years of subs and got $3,500. I got $560 in NY

      1. Kuy says:

        You want proof?

        1. Kuy says:

          I only would get brand name. I was allergic to generic. One script of 90 BRAND name subs was $925

        2. Kuy says:

          Your Repealer Claimed Amount: $125,260.00
          Your Repealer Adjusted Claim Amount: $87,360.00
          Your Non-Repealer Claimed Amount: $0.00
          Your Non-Repealer Adjusted Claim Amount: $0.00

          My check amount was exactly: $13,070.16

  4. Ted says:

    I got $3,800. My claim was 45k. I’m in Cali.

  5. Al says:

    I got 164 bucks… All I did was fill out the little postcard they sent me 3 years ago. Kinda thought I’d get more but whatever’s

    1. Ted says:

      How much did you claim you paid?

      1. Al says:

        I am honestly not sure. Did that postcard have a section to put a claim amount? I just don’t remember.. also did you have send documents related to the claim amount you put down? Or did they take you for your word?

      2. Al z says:

        I am honestly not sure. Did that postcard have a section to put a claim amount? I just don’t remember.. also did you have send documents related to the claim amount you put down? Or did they take you for your word?

1 14 15 16

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.